Can Older Breast Cancer Patients Tolerate Immunotherapy Plus Chemotherapy?

Using a newer combination of immunotherapy and lower doses of chemotherapy, USC Norris Comprehensive Cancer Center experts treated a 79-year-old woman with triple-negative breast cancer.

By
October 2, 2025
7 min

Keck Medicine of USC

Overview

{'add': 'Specify the chemotherapy regimen used.'}

Background

{'add': 'Include statistics on TNBC incidence in older patients.'}

Data Highlights

{'remove': 'Placeholder text and clarify data availability.'}

Key Findings

{'add': 'Include monitoring for specific side effects.'}

Clinical Implications

{'add': 'Suggest specific monitoring strategies.'}

Conclusion

{'add': 'Emphasize individualized treatment plans.'}

References

Freedman RA, Hurria A, The ASCO Post, 2017 -- Accrual of Older Patients to Breast Cancer Trials: A Critical Need
Tamirisa K, et al., The ASCO Post, 2020 -- Does Adjuvant Chemotherapy Improve Survival Among Older Patients With ER-Positive, Node-Positive Breast Cancer and Multiple Comorbidities?
Crozier JA, et al., The ASCO Post, 2021 -- Chemotherapy Added to Local Therapy Improves Overall Survival in Older Women With Triple-Negative Breast Cancer KEY POINTS
the asco post — Response to Immune Checkpoint Inhibitors Not Affected by Age
Early-stage immuno prolongs OS in triple-negative breast cancer
Adjuvant Chemotherapy Outcomes in Older Adults With Nonmetastatic Triple-Negative Breast Cancer - PMC
Anthracycline-Free Chemotherapy and Immunotherapy Regimen for the Treatment of Triple-Negative Breast Cancer Patients at Risk for Cardiotoxicity, NeoCARD Trial - NCI

Can Older Breast Cancer Patients Tolerate Immunotherapy Plus Chemotherapy?